Browsing by Subject "Tissue Plasminogen Activator"
Now showing items 1-14 of 14
-
Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
(JAMA, 2020-06)Importance:Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. ... -
Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system.
(The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011-10)Spinal cord injury (SCI) causes permanent debilitation due to the inability of axons to grow through established scars. Both the sugar chains and core proteins of chondroitin sulfate proteoglycans (CSPGs) are inhibitory ... -
Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis.
(Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020-12-18)<h4>Objectives</h4>The efficacy of thrombolytic therapy with tissue plasminogen activator (tPA) is highly time dependent. Although clinical guidelines do not recommend written informed consent as it may cause treatment delays, ... -
Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke.
(JAMA neurology, 2019-04)Importance:Although overall stroke incidence and mortality in the United States is improving, little is known about the characteristics and clinical outcomes of acute ischemic stroke in Asian American individuals. Objective:To ... -
Development and initial testing of the stroke rapid-treatment readiness tool.
(J Neurosci Nurs, 2014-10)No instruments are currently available to help health systems identify target areas for reducing door-to-needle times for the administration of intravenous tissue plasminogen activator to eligible patients with ischemic ... -
Emergency medical services use and its association with acute ischaemic stroke evaluation and treatment in Singapore.
(Stroke and vascular neurology, 2020-06)<h4>Background</h4>Emergency medical services (EMS) is a critical link in the chain of stroke survival. We aimed to assess EMS use for stroke in Singapore, identify characteristics associated with EMS use and the association ... -
Hospital distance, socioeconomic status, and timely treatment of ischemic stroke.
(Neurology, 2019-08)OBJECTIVE:To determine whether lower socioeconomic status (SES) and longer home to hospital driving time are associated with reductions in tissue plasminogen activator (tPA) administration and timeliness of the treatment. ... -
Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.
(J Am Heart Assoc, 2015-07-22)BACKGROUND: Timely thrombolytic therapy can improve stroke outcomes. Nevertheless, the ability of US hospitals to meet guidelines for intravenous tissue plasminogen activator (tPA) remains suboptimal. What is unclear is ... -
Quality of Care and Outcomes for Patients With Stroke in the United States Admitted During the International Stroke Conference.
(Journal of the American Heart Association, 2018-11)Background Patients presenting to hospitals during non-weekday hours experience worse outcomes, often attributed to reduced staffing. The American Heart Association International Stroke Conference ( ISC ) is well attended ... -
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
(Journal of the American Heart Association, 2019-10-09)Background The impact of estimated glomerular filtration rate (eGFR) on clinical short-term outcomes after stroke thrombolysis with tissue plasminogen activator remains controversial. Methods and Results We analyzed 18 320 ... -
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
(JAMA neurology, 2016-01)Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, many patients may have been receiving antiplatelet therapy before acute ischemic stroke and could face an increased ... -
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
(JAMA, 2012-06)Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated ... -
Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke.
(Neurology, 2019-06)OBJECTIVE:To determine whether young adults (≤40 years old) with acute ischemic stroke are less likely to receive IV tissue plasminogen activator (tPA) and more likely to have longer times to brain imaging and treatment. ... -
Unmasking Proteolytic Activity for Adult Visual Cortex Plasticity by the Removal of Lynx1.
(The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015-09)<h4>Unlabelled</h4>Experience-dependent cortical plasticity declines with age. At the molecular level, experience-dependent proteolytic activity of tissue plasminogen activator (tPA) becomes restricted in the adult brain ...
